Madrigal (MDGL) Reports Q1 2026 Earnings with Strong Growth in Rezdiffra Sales
Madrigal (MDGL) reported Q1 2026 earnings with net sales of $311.3 million, a 127% year-over-year increase, driven by rising demand for Rezdiffra. The company noted over 42,250 active patients on Rezdiffra and a trailing 12-month net sales figure exceeding $1.1 billion, indicating strong market adoption.
Tickers: $MDGL
Topics: blockbuster drug patient growth pharmaceuticals sales growth